TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (Renoir)
Condition:   Rheumatoid Arthritis Interventions:   Drug: ANB030;   Drug: Placebo Sponsor:   AnaptysBio, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials